Clinical Trial Update: Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tislelizumab with chemotherapy for conversion therapy in locally nonresectable esophageal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma
• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Esophageal Squamous Cell Carcinoma, Locally Advanced Carcinoma | Phase 2 | Status: UNKNOWN